Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)

Bone Marrow Transplantation volume 35, pages 165–169 (2005)Cite this article

Abstract

Summary:

Thalidomide is effective in multiple myeloma (MM), even in patients who have relapsed after high-dose therapy. A potent graft-versus-myeloma (GVM) effect can be induced against MM after allogeneic stem cell transplantation (allo-SCT). In all, 31 MM patients received thalidomide as a salvage therapy after progression following allo-SCT. The median maximum daily dose of thalidomide was 200 mg (range, 50–600). Thalidomide had to be discontinued in six patients (19%) because of toxicity. In all, nine patients (29%; 95% CI, 13–45) achieved an objective response with thalidomide therapy (six partial and three very good partial responses, VGPR). Five patients developed graft-versus-host disease (GVHD) after thalidomide therapy, including the three patients achieving a VGPR. These data demonstrate that thalidomide is potentially effective in MM patients failing allo-SCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.

    Article  CAS  Google Scholar 

  2. Yakoub-Agha I, Attal M, Dumontet C et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients – report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002; 3: 185–192.

    Article  CAS  Google Scholar 

  3. Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196–1198.

    CAS  Google Scholar 

  4. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031–3037.

    Article  CAS  Google Scholar 

  5. Lokhorst HM, Segeren CM, Verdonck LF et al. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 2003; 21: 1728–1733.

    Article  Google Scholar 

  6. Mehta J, Singhal S . Graft-versus-myeloma. Bone Marrow Transplant 1998; 22: 835–843.

    Article  CAS  Google Scholar 

  7. Gahrton G, Svensson H, Cavo M et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209–216.

    Article  CAS  Google Scholar 

  8. Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179–1184.

    Article  CAS  Google Scholar 

  9. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787–2793.

    CAS  Google Scholar 

  10. Badros A, Barlogie B, Morris C et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574–2579.

    Article  CAS  Google Scholar 

  11. Badros A, Barlogie B, Siegel E et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295–1303.

    Article  Google Scholar 

  12. Kroger N, Sayer HG, Schwerdtfeger R et al. Unrelated stem cell transplantation in multiple myeloma after a reduced- intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919–3924.

    Article  CAS  Google Scholar 

  13. Majolino R . Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2003; 27: 1037–1043.

    Google Scholar 

  14. Maloney DG, Molina AJ, Sahebi F et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454.

    Article  CAS  Google Scholar 

  15. Mohty M, Boiron JM, Damaj G et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 77–84.

    Article  CAS  Google Scholar 

  16. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  Google Scholar 

  17. Biagi JJ, Mileshkin L, Grigg AP et al. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001; 28: 1145–1150.

    Article  CAS  Google Scholar 

  18. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.

    Article  CAS  Google Scholar 

  19. Vogelsang GB, Farmer ER, Hess AD et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326: 1055–1058.

    Article  CAS  Google Scholar 

  20. Mohty M, Stoppa AM, Blaise D et al. Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J Leukoc Biol 2002; 72: 939–945.

    CAS  PubMed  Google Scholar 

  21. Chao NJ, Parker PM, Niland JC et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs-host disease. Biol Blood Marrow Transplant 1996; 2: 86–92.

    CAS  Google Scholar 

  22. Richardson P, Schlossman R, Jagannath S et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004; 79: 875–882.

    Article  CAS  Google Scholar 

  23. Davies FE, Raje N, Hideshima T et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216.

    Article  CAS  Google Scholar 

  24. Lauwerys BR, Garot N, Renauld JC et al. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol 2000; 165: 1847–1853.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Mohamad Mohty would like to thank the ‘Association Sang pour Cent la Vie’ (Paris, France), the ‘Ligue Départementale contre le Cancer du Gard’ (Nimes, France), the ‘Association Méditerranéenne pour le Développement de la Transplantation’ (AMDT, Marseille, France), the ‘Association Laurette Fuguain’ (Paris, France), the ‘Association pour la Recherche sur le Cancer (ARC)’, the ‘Ligue Nationale contre le Cancer’, the ‘Etablissement Français des Greffes (EFG)’ and the GEFLUC for their generous and continuous support for our ongoing basic and clinical research work.

Author information

Authors and Affiliations

  1. Unité de Transplantation et de Thérapie Cellulaire (UTTC), Institut Paoli-Calmettes, Marseille, France

    M Mohty & D Blaise

  2. Service d'hématologie, CHU de Toulouse, France

    M Attal

  3. Service d'hématologie, CHU de Bordeaux, France

    G Marit

  4. Service d'hématologie, CHU de Besançon, France

    C E Bulabois & J Y Cahn

  5. Service d'hématologie, CHU de Grenoble, France

    F Garban & J J Sotto

  6. Service d'hématologie, CHU de Nice, France

    N Gratecos

  7. Service d'hématologie, Hôtel dieu, Paris, France

    B Rio

  8. Service d'hématologie, Pitié-Salpétrière, Paris, France

    J P Vernant

  9. Service des Maladies du Sang, CHRU, Lille, France

    J P Jouet, T Facon & I Yakoub-Agha

Authors
  1. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Attal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Marit
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C E Bulabois
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Garban
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Gratecos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Rio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J P Vernant
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J J Sotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Y Cahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J P Jouet
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Facon
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. I Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I Yakoub-Agha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mohty, M., Attal, M., Marit, G. et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 35, 165–169 (2005). https://doi.org/10.1038/sj.bmt.1704756

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704756

Keywords

This article is cited by

Search

Advanced search

Quick links